As a result of advances in biomedical research in cancer, molecular genetic testing is increasingly used in oncology, either to identify individuals at risk of developing cancer or to tailor treatment for cancer patients. This describes what is now called "precision medicine", which creates great enthusiasm among the general population, decision-makers and healthcare professionals. Although this new approach is promising, the introduction of genetic testing into clinical practice and the use of targeted therapies adapted to patients' genetic profile raise a number of important questions that require urgent attention.
Some of these questions are: What is the impact of these innovations on the organization and coordination of healthcare services in oncology? Are healthcare professionals adequately trained to adopt these innovations? What is the impact of genetic testing on care trajectories of cancer patients and their clinical outcomes? Are there social and regional disparities in access to genetic testing and targeted therapies? What are the side effects of targeted therapies when compared to conventional therapies in real-world settings? What is the impact of these therapies on the quality of life of patients, the use and costs of health services? The main purpose of the teMPO research program is to help answer these key questions.
The results of this research will provide useful information to decision-makers and health professionals in Québec and elsewhere and they will be able to finely appreciate the benefits, limitations of the integration of molecular genetic testing and targeted therapies in routine clinical practice.